Showing 1071-1080 of 19239 results for "".
Resectable Head & Neck Cancer: A Team-Based Approach to Perioperative Immunotherapy
https://reachmd.com/programs/cme/resectable-head-neck-cancer-a-team-based-approach-to-perioperative-immunotherapy/35705/Resectable Head & Neck Cancer: A Team-Based Approach to Perioperative ImmunotherapyClinical Evidence on Monotherapy With Menin Inhibitors in R/R AML
https://reachmd.com/programs/cme/clinical-evidence-on-monotherapy-with-menin-inhibitors-in-rr-aml/36180/Explore advances in AML that integrate risk stratification, molecular profiling, and menin-targeted therapies to optimize care and improve outcomes.Employing Immunotherapy and ADCs in Advanced Endometrial and Cervical Cancers: Current and Emerging Therapies
https://reachmd.com/programs/cme/employing-immunotherapy-and-adcs-in-advanced-endometrial-and-cervical-cancers-current-and-emerging-therapies/14460/Our experts are breaking down evolving treatments for advanced endometrial & cervical cancer. Hear the latest data on immunotherapy and ADCs now!Updates in Major Depressive Disorder with Insomnia
https://reachmd.com/programs/cme/updates-in-major-depressive-disorder-with-insomnia/36556/Join us to learn about the emerging data in the management of major depressive disorder with insomnia.Case Review: Can You Crack This IBD Case?
https://reachmd.com/programs/cme/case-review-can-you-crack-this-ibd-case/51484/Explore IBD from diagnosis to remission with practical cases, treatment strategies, and a treat-to-target approach for optimal patient outcomes.From Risk to Resilience: Best Practices for Improving Outcomes in Early-Stage ER+/HER2- Breast Cancer
https://reachmd.com/programs/cme/from-risk-to-resilience-best-practices-for-improving-outcomes-in-early-stage-erher2-breast-cancer/32681/Learn about the importance of risk assessment, the role of CDK4/6 inhibitors, and the management of treatment-emergent toxicities in the treatment of HR+, HER2- early breast cancer.Challenging Cases in IgA Nephropathy and Identifying Patients for Specialized Care
https://reachmd.com/programs/medical-industry-feature/challenging-cases-iga-nephropathy-specialized-care/29536/IgA nephropathy is a heterogeneous disease with variable clinical presentation. Learn more about its pathogenesis, diagnostic considerations, and complex cases as Dr. Jaimini Patel sits down with Dr. Sayna Norouzi, Associate Professor of Medicine and clinical nephrologist at Loma Linda University MeInsights for Postmenopausal Osteoporosis Patients at Very High Risk of Fracture
https://reachmd.com/programs/medical-industry-feature/postmenopausal-osteoporosis-high-fracture-risk/27132/Starting with the presence of a prior fracture, advancing age, and bone mineral density, there are numerous factors that increase the risk of fracture in postmenopausal women.1 But despite these common predictors, treatment rates of osteoporosis in postmenopausal women have consistently remained lowNavigating Today and Shaping Tomorrow in ISM: Personalized Strategies With Current and Emerging KIT Inhibitors
https://reachmd.com/programs/cme/navigating-today-and-shaping-tomorrow-in-ism-personalized-strategies-with-current-and-emerging-kit-inhibitors/54388/Explore the latest clinical evidence on current and emerging KIT tyrosine kinase inhibitors in indolent systemic mastocytosis to optimize patient care.Kappa Free Light Chain Index in the Diagnosis of Multiple Sclerosis
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/kappa-free-light-chain-index-in-the-diagnosis-of-multiple-sclerosis/54598/Adoption of the kappa free light chain index can enhance diagnostic accuracy and reduce latency in multiple sclerosis diagnosis, complementing MRI and expert assessment in clinical decision-making.